← Eichor
Condition: Tislelizumab Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Tislelizumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperth
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06685887HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment
NA · 1 location(s) · Shanghai Zhongshan Hospital · NCT06794073Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-r
Phase 1 · 1 location(s) · First Affiliated Hospital of Chongqing Medical University · NCT06916494Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase II
Phase 3 · 1 location(s) · Fujian Cancer Hospital · NCT06793917Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07125547JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit
Phase 3 · 37 location(s) · Allist Pharmaceuticals, Inc. · NCT06416410Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07528274Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06323382tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Phase 3 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06332274Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
Phase 1 · 1 location(s) · West China Hospital · NCT07565740Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07609121TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory
Phase 2 · 1 location(s) · Eye & ENT Hospital of Fudan University · NCT07370337A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
Phase N/A · 2 location(s) · Southwest Hospital, China · NCT06760858Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squa
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07147426Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally U
Phase 2 · 1 location(s) · Fuzhou General Hospital · NCT05515315Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Mon
Phase 3 · 36 location(s) · ImmunityBio, Inc. · NCT06745908XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Tr
Phase 2 · 11 location(s) · German CLL Study Group · NCT04271956A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophag
Phase 3 · 1 location(s) · Renmin Hospital of Wuhan University · NCT05919030Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Inte
Phase 3 · 1 location(s) · Fujian Medical University Union Hospital · NCT06441110A Retrospective Real-World Study Based on RATIONALE-307
Phase N/A · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07478809Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Chol
Phase 2 · 1 location(s) · Fudan University · NCT06860477Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT06646588A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable
Phase 1 · 4 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT07059299A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07671339Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capec
Phase 2 · 2 location(s) · Affiliated Cancer Hospital of Shantou University Medical Col · NCT07104604
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.